NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

This roundtable series provides context on the growing number of options for patients with non–small cell lung cancer and KRAS G12C mutations, as discussed by key opinion leaders and participants at virtual live events.

Targeted Therapy Options for Patients With KRAS-Mutated NSCLC

Adagrasib Plus Pembrolizumab Shows Best Efficacy in PD-L1–High NSCLC

Adagrasib Plus Pembrolizumab Shows Best Efficacy in PD-L1–High NSCLC

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with non–small cell lung cancer.

KRAS Inhibitors Show Efficacy in Randomized NSCLC Trials

KRAS Inhibitors Show Efficacy in Randomized NSCLC Trials

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.

Physicians Discuss Rebiopsy Options Before Second-Line NSCLC Therapy

Physicians Discuss Rebiopsy Options Before Second-Line NSCLC Therapy

February 17, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Anne S. Tsao discussed with participants

Adagrasib Shows Efficacy and Tolerability in KRAS G12C–Mutated NSCLC

Adagrasib Shows Efficacy and Tolerability in KRAS G12C–Mutated NSCLC

December 07, 2022

Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.